Bristol-Myers Squibb vs D.R. Horton Inc.
Side-by-side earnings signal comparison from SEC quarterly filings
Verdict
Bristol-Myers Squibb (BMY) carries a "Neutral" signal with -3.4% revenue growth, while D.R. Horton Inc. (DHI) is "Neutral" with -0.7% revenue growth. Both companies report in the Healthcare and Consumer Discretionary sectors.
| Metric | Bristol-Myers Squibb (BMY) | D.R. Horton Inc. (DHI) |
|---|---|---|
| Operator Signal | Neutral | Neutral |
| Signal Confidence | HIGH | HIGH |
| Latest Revenue | $11.5B | $7.6B |
| Revenue Growth | -3.4% | -0.7%* |
| Latest EPS | $1.31 | $2.24* |
| EPS Growth | 118.3%* | -14.2% |
| Sector | Healthcare | Consumer Discretionary |
| Quarters Tracked | 8 | 8 |
Bristol-Myers Squibb (BMY) carries a "Neutral" signal with -3.4% revenue growth, while D.R. Horton Inc. (DHI) is "Neutral" with -0.7% revenue growth. Both companies report in the Healthcare and Consumer Discretionary sectors.
Explore More
Related Comparisons
Healthcare peer
Healthcare peer
Healthcare peer
Healthcare peer
Consumer Discretionary peer
Consumer Discretionary peer
Consumer Discretionary peer
Consumer Discretionary peer
Related Earnings
The side-by-side above pulls the SEC EDGAR 8-K filings data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: SEC EDGAR 10-K filings, 2026.